BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS
2026-04-20
This study demonstrates that BRD4 inhibitors, including I-BET-762, significantly sensitize diverse cell lines to erastin-induced ferroptosis by promoting ROS accumulation and suppressing FSP1 expression. The findings clarify the mechanistic interplay between BET inhibition and ferroptosis, providing a foundation for combination strategies in cancer biology.
FLOT1–FOSL2–EphA2 Axis: Modulating Microglial Polarization i
2026-04-20
This study uncovers a mechanistic pathway in Alzheimer's disease whereby the interaction of FLOT1 with FOSL2 upregulates EphA2, driving microglial polarization toward a pro-inflammatory, neurotoxic state. Targeting this pathway reduced neuroinflammation and improved cognitive outcomes in mouse models, highlighting new therapeutic potential for modulating microglial function in neurodegenerative disease.
ML-7 Hydrochloride in MLCK Pathway Dissection: Mechanistic I
2026-04-19
Explore the unique role of ML-7 hydrochloride as a myosin light chain kinase inhibitor in dissecting MLCK-mediated phosphorylation, with deep reference to endocytosis models and actionable assay protocols. Gain advanced understanding for cardiovascular and cell biology research.
Molidustat (BAY85-3934): Optimizing HIF Stabilization Workfl
2026-04-18
Molidustat (BAY85-3934) is a next-generation HIF-PH inhibitor that enables robust, physiologically relevant erythropoietin stimulation for renal anemia and oxygen-sensing pathway research. This guide details advanced workflow integration, protocol parameters, and troubleshooting based on both empirical evidence and recent mechanistic discoveries.
Substance P (B6620): Technical Guide for CNS and Inflammatio
2026-04-17
Substance P (SKU B6620) is a high-purity tachykinin neuropeptide for researchers studying pain transmission, neuroinflammation, and immune modulation via the neurokinin-1 pathway. This article clarifies optimal handling, protocol parameters, and technical boundaries for its use in CNS and inflammation models. It is not suitable for diagnostic or clinical applications.
MG-132 (Z-LLL-al): Optimizing Proteasome Inhibitor Workflows
2026-04-16
MG-132 (Z-LLL-al) empowers researchers to dissect the ubiquitin-proteasome system in cancer, cell cycle, and oxidative stress models. This guide translates advanced mechanistic insights into actionable protocols and troubleshooting strategies, maximizing the impact of APExBIO’s MG-132 in apoptosis and proteostasis research.
CH 223191: Transforming AhR Antagonism for Translational Res
2026-04-15
This thought-leadership article explores the mechanistic and translational potential of CH 223191—a potent aryl hydrocarbon receptor antagonist—in modern biomedical research. Integrating recent evidence on the microbiota–tryptophan–AhR axis and epithelial regeneration, it provides strategic guidance for deploying CH 223191 in environmental toxicology, stem cell biology, and disease models, while defining protocol parameters and translational outlooks.
Palomid 529 (P529): Advancing PI3K/Akt/mTOR Inhibition for O
2026-04-14
Discover how Palomid 529 (P529) uniquely advances cancer research by targeting PI3K/Akt/mTOR-driven metastasis and therapy resistance. This in-depth analysis integrates the latest mechanistic insights and practical protocols, offering a fresh perspective for translational oncology.
Belinostat (PXD101): Precision Tools for HDAC Inhibition Ass
2026-04-13
Explore how Belinostat (PXD101), a potent pan-HDAC inhibitor, enables advanced, quantitative analysis of tumor cell responses. This article uniquely connects in vitro assay design with mechanistic insights and decision-making for epigenetic cancer research.
Bazedoxifene Targets IL-6/GP130 Signaling for Cancer Therapy
2026-04-12
This review synthesizes evidence for bazedoxifene (BZA) as a novel inhibitor of the IL-6/GP130 signaling pathway—a central axis in cancer proliferation and survival. The article delineates BZA’s mechanism, preclinical potential, and comparison to established DNA synthesis inhibitors, informing future designs of targeted cancer research workflows.
Necrostatin 2 (Nec-2): Optimizing Necroptosis Inhibition Wor
2026-04-12
Necrostatin 2 (Nec-2) is a precision RIPK2 kinase inhibitor that empowers researchers to dissect necroptosis with high specificity, supporting robust experimental workflows from cell-based assays to in vivo disease modeling. This guide delivers actionable protocol enhancements, troubleshooting insights, and cross-references novel membrane remodeling biology for cutting-edge ischemic stroke and cell death research.
Fasudil (HA-1077) HCl: Precision ROCK Inhibition in Cell Mod
2026-04-11
Fasudil (HA-1077) HCl from APExBIO stands out for selective, robust Rho/ROCK pathway inhibition, enabling reproducible control over cell proliferation, migration, and apoptosis in cancer and disease models. This guide translates the latest research and real-world troubleshooting into practical protocols that maximize experimental reliability and data clarity.
Latrunculin A: Precision Use in Actin Cytoskeleton Disruptio
2026-04-11
Latrunculin A, a reversible inhibitor of actin assembly, is redefining how cell biologists dissect cytoskeletal dynamics and viral pathogenesis. This article delivers protocol-driven workflows, troubleshooting strategies, and data-backed guidance for maximizing the impact of Latrunculin A (APExBIO, SKU B7555) in advanced cell morphology and motility research.
SAR131675: Selective ATP-Competitive VEGFR-3 Inhibitor in...
2026-04-10
SAR131675 stands out as a highly selective ATP-competitive VEGFR-3 inhibitor, empowering researchers to dissect the lymphangiogenesis and tumor angiogenesis pathways with precision. Its robust anti-lymphangiogenic and anti-angiogenic properties, paired with minimal off-target effects, make it the benchmark tool for preclinical studies targeting VEGFR signaling and metastatic progression.
SAR131675, a Selective and ATP-Competitive VEGFR-3 Inhibi...
2026-04-09
This article presents evidence-based strategies for leveraging SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301), in cell-based and translational studies targeting lymphangiogenesis, angiogenesis, and tumor biology. Drawing on validated protocols and peer-reviewed data, it addresses real-world laboratory challenges in assay design, compound selectivity, and workflow optimization. Researchers will gain actionable insights into maximizing reproducibility and data fidelity with SAR131675.
466 records 22/32 page Previous Next First page 上5页 2122232425 下5页 Last page